TGFB1 and idiopathic pulmonary fibrosis: Overall, the developed inhalable siIL11@PPGC NPs target the downstream IL11 and avoid the adverse effects associated with inhibition of TGF-β1 directly or indirectly (47, 48), offering a safe, noninvasive, and potent therapeutic approach for IPF treatment.